Nonspecific mitogen responses of peripheral lymphocytes in levamisole-treated patients with herpetic stromal keratitis. 1984

H Sakata, and N Hiyama, and H Kondo, and Y Hirakawa, and H Yoshida

UI MeSH Term Description Entries
D007635 Keratitis, Dendritic A form of herpetic keratitis characterized by the formation of small vesicles which break down and coalesce to form recurring dendritic ulcers, characteristically irregular, linear, branching, and ending in knoblike extremities. (Dictionary of Visual Science, 3d ed) Furrow Keratitis,Keratitis, Furrow,Dendritic Keratitides,Dendritic Keratitis,Furrow Keratitides,Keratitides, Dendritic,Keratitides, Furrow
D007978 Levamisole An antihelminthic drug that has been tried experimentally in rheumatic disorders where it apparently restores the immune response by increasing macrophage chemotaxis and T-lymphocyte function. Paradoxically, this immune enhancement appears to be beneficial in rheumatoid arthritis where dermatitis, leukopenia, and thrombocytopenia, and nausea and vomiting have been reported as side effects. (From Smith and Reynard, Textbook of Pharmacology, 1991, p435-6) L-Tetramisole,Levotetramisole,Decaris,Dekaris,Levamisole Hydrochloride,Solaskil,Hydrochloride, Levamisole
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008934 Mitogens Substances that stimulate mitosis and lymphocyte transformation. They include not only substances associated with LECTINS, but also substances from streptococci (associated with streptolysin S) and from strains of alpha-toxin-producing staphylococci. (Stedman, 25th ed) Mitogen,Phytomitogen,Phytomitogens
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000276 Adjuvants, Immunologic Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. Immunoactivators,Immunoadjuvant,Immunoadjuvants,Immunologic Adjuvant,Immunopotentiator,Immunopotentiators,Immunostimulant,Immunostimulants,Adjuvant, Immunologic,Adjuvants, Immunological,Immunologic Adjuvants,Immunological Adjuvant,Adjuvant, Immunological,Immunological Adjuvants
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral

Related Publications

H Sakata, and N Hiyama, and H Kondo, and Y Hirakawa, and H Yoshida
January 1987, Voprosy meditsinskoi khimii,
H Sakata, and N Hiyama, and H Kondo, and Y Hirakawa, and H Yoshida
January 1980, Revista de chirurgie, oncologie, radiologie, o. r. l., oftalmologie, stomatologie. Seria: Oftalmologie,
H Sakata, and N Hiyama, and H Kondo, and Y Hirakawa, and H Yoshida
September 2001, Journal of immunology (Baltimore, Md. : 1950),
H Sakata, and N Hiyama, and H Kondo, and Y Hirakawa, and H Yoshida
August 1984, Investigative ophthalmology & visual science,
H Sakata, and N Hiyama, and H Kondo, and Y Hirakawa, and H Yoshida
April 1981, Annals of ophthalmology,
H Sakata, and N Hiyama, and H Kondo, and Y Hirakawa, and H Yoshida
September 1985, [Zhonghua yan ke za zhi] Chinese journal of ophthalmology,
H Sakata, and N Hiyama, and H Kondo, and Y Hirakawa, and H Yoshida
June 1992, Investigative ophthalmology & visual science,
H Sakata, and N Hiyama, and H Kondo, and Y Hirakawa, and H Yoshida
June 1986, Presse medicale (Paris, France : 1983),
H Sakata, and N Hiyama, and H Kondo, and Y Hirakawa, and H Yoshida
November 2023, Molecular therapy : the journal of the American Society of Gene Therapy,
H Sakata, and N Hiyama, and H Kondo, and Y Hirakawa, and H Yoshida
January 2015, Survey of ophthalmology,
Copied contents to your clipboard!